Home Microbiology Antibiotics chemical Minocycline HCl

research use only

Minocycline HCl Antibiotics chemical

Cat.No.S4226

Minocycline HCl is the most lipid soluble and most active tetracycline antibiotic, binds to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.
Minocycline HCl Antibiotics chemical Chemical Structure

Chemical Structure

Molecular Weight: 493.94

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability

Quality Control

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jurkat cells Cell viability assay 10-200 µM 24 h reduces cell viability and induces DNA fragmentation and dissipation of the mitochondrial membrane potential in Jurkat cells but is harmless to human peripheral blood lymphocyte cells (hPBLCs)
hPBLCs Cell viability assay 10-200 µM 24 h reduces cell viability and induces DNA fragmentation and dissipation of the mitochondrial membrane potential in Jurkat cells but is harmless to human peripheral blood lymphocyte cells (hPBLCs)
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight 493.94 Formula

C23H27N3O7.HCl

 Storage (From the date of receipt)
CAS No. 13614-98-7 Download SDF Storage of Stock Solutions

Synonyms CL 59806 Smiles CN(C)C1C2CC3CC4=C(C=CC(=C4C(=C3C(=O)C2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C.Cl

Solubility

In vitro
Batch:

Water : 6 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro

Minocycline is a second-generation tetracycline used in humans, which effectively crosses the blood−brain barrier. It inhibits the activity of caspase-1, caspase-3, inducible form of nitric oxide synthetase (iNOS) and p38 mitogen-activated protein kinase (MAPK). After experimental ischemia, minocycline inhibits caspase-1 and inducible nitric oxide synthetase (iNOS) upregulation, and decreases infarct size. Minocycline inhibits mitochondrial permeability-transition-mediated cytochrome c release. Minocycline-mediated inhibition of cytochrome c release is demonstrated in vivo, in cells, and in isolated mitochondria. [2]
In vivo

Minocycline is a semi-synthetic tetracycline derivative which is well absorbed and distributed in body tissues and is suitable for twice daily administration. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). [1]

Minocycline is remarkable neuroprotective qualities in models of cerebral ischaemia, traumatic brain injury, and Huntington's and Parkinson's disease. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging. [3]
References

Applications

Methods Biomarkers Images PMID
Western blot IL-6Rα / gp130 p-STAT3 / STAT3 / Mcl-1 / p-ERK / ERK S4226-WB1 23593315
Immunofluorescence p-STAT3 STAT3 S4226-IF1 23593315
Growth inhibition assay Cell viability S4226-viability1 27555377

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05605366 Not yet recruiting
Sickle Cell Disease|Cognitive Impairment|Cognitive Decline|Cognitive Change|Cognitive Dysfunction|Cognitive Deficit|Neuroinflammatory Response
University of Cincinnati
 June 1 2024 Phase 1
NCT05861258 Recruiting
Mycobacterium Avium Complex Pulmonary Disease
Radboud University Medical Center
 May 8 2023 Phase 2
NCT05630534 Not yet recruiting
Intracerebral Hemorrhage
Second Affiliated Hospital School of Medicine Zhejiang University|The Fourth Affiliated Hospital of Zhejiang University School of Medicine|The Second Affiliated Hospital of Jiaxing University
 January 1 2023 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.